Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to ease chemo side effect monitoring for breast cancer patients

NCT ID NCT05743686

Symptom relief Sponsor: Julie Lemieux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a smartphone app that lets breast cancer patients on oral chemotherapy report side effects and get basic advice. Hospital pharmacists were alerted when needed. The goal was to see if the app could improve monitoring and reduce phone calls. Only 28 patients took part, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smartphone app for symptom reporting
What this could lead to
If it works, this app could help patients manage side effects better and reduce unnecessary calls to healthcare teams.
What could go wrong
This is a very small pilot study with only 28 participants and no control group, so results may not apply widely. The app's benefit on survival or quality of life is not proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>=18 years of age * metastatic breast cancer * receiving oral chemotherapy (palbociclib, everolimus, or capecitabine) * possess an smartphone, a tablet, or a personal compiter Exclusion Criteria: * cognitive impairments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm chemotherapy-induced toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms Chemotherapeutic toxicity

Contacts and locations

Locations

  • St-Sacrement Hospital

    Québec, Quebec, G1S4L8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.